Beverly Alston
About
Beverly Alston is a scholar working on Infectious Diseases, Virology and Epidemiology.
According to data from OpenAlex, Beverly Alston has authored 19 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 8 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Beverly Alston's work include HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (8 papers) and HIV-related health complications and treatments (7 papers). Beverly Alston is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (8 papers) and HIV-related health complications and treatments (7 papers). Beverly Alston collaborates with scholars based in United States and Israel. Beverly Alston's co-authors include Judith A. Aberg, Carl J. Fichtenbaum, Kenneth E. Sherman, Marion G. Peters, Margaret James Koziel, Raymond T. Chung, Charles van der Horst, Janet Andersen, Tun Liu and Atul K. Bhan and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Beverly Alston
19 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Beverly Alston United States | 13 | 837 | 796 | 722 | 527 | 349 | 19 | 1.7k | ||
| Paolo Sacchi Italy | 24 | 828 1.0× | 808 1.0× | 645 0.9× | 472 0.9× | 270 0.8× | 115 | 2.2k | ||
| G Scullard United Kingdom | 20 | 659 0.8× | 914 1.1× | 643 0.9× | 245 0.5× | 471 1.3× | 29 | 1.8k | ||
| Giorgio Barbarini Italy | 31 | 762 0.9× | 1.4k 1.7× | 963 1.3× | 580 1.1× | 427 1.2× | 88 | 2.5k | ||
| JK Rockstroh Germany | 19 | 782 0.9× | 775 1.0× | 417 0.6× | 172 0.3× | 420 1.2× | 63 | 1.9k | ||
| Mark Bloch Australia | 17 | 669 0.8× | 351 0.4× | 306 0.4× | 481 0.9× | 391 1.1× | 40 | 1.5k | ||
| Natasa Rajicic United States | 18 | 496 0.6× | 715 0.9× | 632 0.9× | 215 0.4× | 293 0.8× | 33 | 1.7k | ||
| Markus Bickel Germany | 25 | 1.1k 1.3× | 691 0.9× | 154 0.2× | 638 1.2× | 657 1.9× | 73 | 1.9k | ||
| Beverly Alston‐Smith United States | 13 | 421 0.5× | 329 0.4× | 187 0.3× | 610 1.2× | 281 0.8× | 23 | 1.0k | ||
| Marina Núñez Spain | 33 | 1.5k 1.8× | 2.3k 2.8× | 2.3k 3.2× | 329 0.6× | 490 1.4× | 104 | 3.4k | ||
| Kitty Yale United States | 16 | 1.2k 1.4× | 646 0.8× | 230 0.3× | 389 0.7× | 837 2.4× | 21 | 1.9k |
Countries citing papers authored by Beverly Alston
Since
Specialization
Citations
This map shows the geographic impact of Beverly Alston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beverly Alston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beverly Alston more than expected).
Fields of papers citing papers by Beverly Alston
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Beverly Alston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beverly Alston. The network helps show where Beverly Alston may publish in the future.
Co-authorship network of co-authors of Beverly Alston
This figure shows the co-authorship network connecting the top 25 collaborators of Beverly Alston. A scholar is included among the top collaborators of Beverly Alston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beverly Alston. Beverly Alston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sherman, Kenneth E., Janet W. Andersen, Adeel A. Butt, et al.. (2010). Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(5). 597–605.
2.
Kang, Min‐Hee, et al.. (2007). Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Medicine. 8(5). 288–294.
3.
Bhasin, Shalender, Robert A. Parker, Fred R. Sattler, et al.. (2006). Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity. The Journal of Clinical Endocrinology & Metabolism. 92(3). 1049–1057.
4.
Aberg, Judith A., Susan L. Rosenkranz, Carl J. Fichtenbaum, et al.. (2006). Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 20(5). 725–729.
5.
Aberg, Judith A., Robert Zackin, Susan W. Brobst, et al.. (2005). A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Research and Human Retroviruses. 21(9). 757–767.
6.
Gerber, John G., Susan L. Rosenkranz, Carl J. Fichtenbaum, et al.. (2005). Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin. JAIDS Journal of Acquired Immune Deficiency Syndromes. 39(3). 307–312.
7.
Wohl, David A., Christopher D. Pilcher, Scott B. Evans, et al.. (2004). Absence of Sustained Hyperlactatemia in HIV-Infected Patients With Risk Factors for Mitochondrial Toxicity. JAIDS Journal of Acquired Immune Deficiency Syndromes. 35(3). 274–278.
8.
Borucki, Michael J., John Spritzler, David M. Asmuth, et al.. (2004). A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Research. 64(2). 103–111.
9.
Chung, Raymond T., Janet Andersen, Paul A. Volberding, et al.. (2004). Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. New England Journal of Medicine. 351(5). 451–459.
10.
Shikuma, Cecilia M., Robert Zackin, Fred R. Sattler, et al.. (2004). Changes in Weight and Lean Body Mass during Highly Active Antiretroviral Therapy. Clinical Infectious Diseases. 39(8). 1223–1230.
11.
Borucki, Michael J., John Spritzler, David M. Asmuth, et al.. (2004). A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Research. 64(2). 103–111.
12.
Shiramizu, Bruce, Dickens Theodore, Roland L. Bassett, et al.. (2003). Correlation of Single Photon Emission Computed Tomography Parameters as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in the Setting of HIV and Hepatitis C Virus Coinfection: A Multicenter Trial of the Adult AIDS Clinical Trials Group. JAIDS Journal of Acquired Immune Deficiency Syndromes. 33(3). 329–335.
13.
Fichtenbaum, Carl J., John G. Gerber, Susan L. Rosenkranz, et al.. (2002). Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 16(4). 569–577.
14.
Muth, K, Eunice Yu, Beverly Alston, & Jonas H. Ellenberg. (2001). The Closeout Process for a Clinical Trial Terminated Early for Lagging Enrollment and Inadequate Follow-up. Controlled Clinical Trials. 22(1). 49–55.
15.
Fisher, Evelyn J., Kathryn Chaloner, David L. Cohn, et al.. (2001). The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS. 15(13). 1695–1700.
16.
Alston, Beverly, Jonas H. Ellenberg, Harold C. Standiford, et al.. (1999). A Multicenter, Randomized, Controlled Trial of Three Preparations of Low-Dose Oral α-Interferon in HIV-Infected Patients With CD4+ Counts Between 50 and 350 cells/mm3. JAIDS Journal of Acquired Immune Deficiency Syndromes. 22(4). 348–348.
17.
Alston, Beverly, Jonas H. Ellenberg, Harold C. Standiford, et al.. (1999). A Multicenter, Randomized, Controlled Trial of Three Preparations of Low-Dose Oral α-Interferon in HIV-Infected Patients With CD4+ Counts Between 50 and 350 cells/mm3. JAIDS Journal of Acquired Immune Deficiency Syndromes. 22(4). 348–348.
18.
Brosgart, Carol, Thomas A. Louis, David W. Hillman, et al.. (1998). A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS. 12(3). 269–277.
19.
Schuman, Paula, Linnea Capps, Grace Peng, et al.. (1997). Weekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection. Annals of Internal Medicine. 126(9). 689–696.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paolo Sacchi Breakdown of academic impact, for papers by G Scullard Breakdown of academic impact, for papers by Giorgio Barbarini Breakdown of academic impact, for papers by JK Rockstroh Breakdown of academic impact, for papers by Mark Bloch Breakdown of academic impact, for papers by Natasa Rajicic Breakdown of academic impact, for papers by Markus Bickel Breakdown of academic impact, for papers by Beverly Alston‐Smith Breakdown of academic impact, for papers by Marina Núñez Breakdown of academic impact, for papers by Kitty Yale